PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Acclaims Targos for Rapidly Establishing itself as a Leader in Customer-oriented Biomarker Services - Frost & Sullivan Acclaims Targos for Rapidly Establishing itself as a Leader in Customer-oriented Biomarker Services in the In Vitro Diagnostic Services Market - Frost.com
Frost & Sullivan Acclaims Targos for Rapidly Establishing itself as a Leader in Customer-oriented Biomarker Services

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/03/28 - Frost & Sullivan Acclaims Targos for Rapidly Establishing itself as a Leader in Customer-oriented Biomarker Services in the In Vitro Diagnostic Services Market - Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Targos offers highly standardised clinical biomarker services for the development of the international pharmaceutical and diagnostic industry

Based on its recent analysis of the in vitro diagnostics services market, Frost & Sullivan recognizes Targos Molecular Pathology GmbH with the 2011 European Frost & Sullivan Award for Customer Service Leadership. Targos is uniquely positioned to combine expertise in clinical and molecular pathology and highly standardised biomarker analysis with strict quality assurance.

Targos has superior time lines of service compared to its competitors, which have a turn-around-time (TAT) for not less than four days. Targos, on the other hand, has optimized the TAT for clinical tissue biomarker analysis to as low as 24 hours, enabling faster diagnostic test results and timely delivery of diagnostic services.

"The Targos team has proven its meticulousness, reliability and flexibility in handling small and very large projects to customers' satisfaction," said Frost & Sullivan Research Analyst Srinivas Sashidhar. "It provides a wide range of biomarker and other diagnostic services for histopathology, tissue analysis, expression profiling, enzyme-linked immunosorbent assay (ELISA) testing and related services including project, data and logistic management of biomarker studies."

Its services and expertise have appealed to customers, evidenced by the extension of long-term projects from 5 to 20 years. Targos’ proficiency in in vitro diagnostics services has also allowed it to expand its customer base to more than 30 top pharmaceutical, biotech and diagnostic companies.

Targos has a well-organized cost structure, which can be tailored according to the project or service. The costs include project management, logistics management and data management fees. Its diagnostic service costs are lesser than its competitors’.

"The company has been inspected by the Food and Drug Administration (FDA) and participates in College of American Pathologists (CAP) proficiency testing and lab improvement programmes," notes Sashidhar. "Targos, in collaboration with its pathology partners, has acted as Good Clinical Practice-compliant patho-diagnostic reference centre for more than 75 pharmaco-diagnostic trials."

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in customer service leadership within its industry. The recipient company shows tremendous responsiveness to customer needs and continually focuses on long and short-term customer profitability goals. In addition, it demonstrates flexibility in tailoring its product offerings to suit customer businesses.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Targos Molecular Pathology GmbH
Targos Molecular Pathology GmbH since 2005 has established itself as a preferred service provider for standardized analytics of clinical biomarkers. Targos central lab services allow its customers to perform global diagnostic and pharmaceutical approval trials under strict quality standards and lowest possible turn-around times for molecular pathology analyses. Targos thrives for steady improvement of service quality and portfolio and has currently 70 employees in three German sites.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Acclaims Targos for Rapidly Establishing itself as a Leader in Customer-oriented Biomarker Services

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Emily Bailey - Frost.com 
+44(0)20 7915 7869 emily.bailey[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)